Publications by authors named "Mpumi Maxebengula"

Claim this Profile
A
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.
Angharad G Davis, Sean Wasserman, Cari Stek, Mpumi Maxebengula, C Jason Liang

Clin Infect Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive Impairment in Tuberculous Meningitis.
Angharad G Davis, Anna J Dreyer, Christine Albertyn, Mpumi Maxebengula, Cari Stek

Clin Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.
Sean Wasserman, Angharad Davis, Cari Stek, Maxwell Chirehwa, Stephani Botha, Mpumi Maxebengula

Antimicrob Agents Chemother· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM].
Angharad G Davis, Sean Wasserman, Mpumi Maxebengula, Cari Stek, Marise Bremer

Wellcome Open Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis